| Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial DP Tashkin, MD Roth, PJ Clements, DE Furst, D Khanna, EC Kleerup, ... The lancet Respiratory medicine 4 (9), 708-719, 2016 | 958 | 2016 |
| Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis L van Bon, AJ Affandi, J Broen, RB Christmann, RJ Marijnissen, L Stawski, ... New England journal of medicine 370 (5), 433-443, 2014 | 451 | 2014 |
| Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus TRDJ Radstake, O Gorlova, B Rueda, JE Martin, BZ Alizadeh, ... Nature genetics 42 (5), 426-429, 2010 | 449 | 2010 |
| Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy O Gorlova, JE Martin, B Rueda, BPC Koeleman, J Ying, M Teruel, ... PLoS genetics 7 (7), e1002178, 2011 | 260 | 2011 |
| Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis MD Mayes, L Bossini-Castillo, O Gorlova, JE Martin, X Zhou, WV Chen, ... The American Journal of Human Genetics 94 (1), 47-61, 2014 | 247 | 2014 |
| Systemic sclerosis and lupus: points in an interferon‐mediated continuum S Assassi, MD Mayes, FC Arnett, P Gourh, SK Agarwal, TA McNearney, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2010 | 200 | 2010 |
| Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort S Assassi, R Sharif, RE Lasky, TA McNearney, RM Estrada-Y-Martin, ... Arthritis research & therapy 12, 1-11, 2010 | 182 | 2010 |
| Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations P Gourh, FC Arnett, S Assassi, FK Tan, M Huang, L Diekman, MD Mayes, ... Arthritis research & therapy 11, 1-11, 2009 | 178 | 2009 |
| Predictors of progression in systemic sclerosis patients with interstitial lung disease O Distler, S Assassi, V Cottin, M Cutolo, SK Danoff, CP Denton, ... European Respiratory Journal 55 (5), 2020 | 172 | 2020 |
| A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease D Khanna, R Saggar, MD Mayes, F Abtin, PJ Clements, P Maranian, ... Arthritis & Rheumatism 63 (11), 3540-3546, 2011 | 167 | 2011 |
| Clinical and genetic factors predictive of mortality in early systemic sclerosis S Assassi, D Del Junco, K Sutter, TA McNearney, JD Reveille, A Karnavas, ... Arthritis Care & Research 61 (10), 1403-1411, 2009 | 161 | 2009 |
| Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis S Assassi, WR Swindell, M Wu, FD Tan, D Khanna, DE Furst, DP Tashkin, ... Arthritis & rheumatology 67 (11), 3016-3026, 2015 | 155 | 2015 |
| The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis D Khanna, VJ Berrocal, EH Giannini, JR Seibold, PA Merkel, MD Mayes, ... Arthritis care & research 68 (2), 167-178, 2016 | 153 | 2016 |
| Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial KB Highland, O Distler, M Kuwana, Y Allanore, S Assassi, A Azuma, ... The Lancet Respiratory Medicine 9 (1), 96-106, 2021 | 148 | 2021 |
| Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations P Gourh, SK Agarwal, E Martin, D Divecha, B Rueda, H Bunting, ... Journal of autoimmunity 34 (2), 155-162, 2010 | 144 | 2010 |
| Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients S Assassi, MJ Fritzler, FC Arnett, GL Norman, KR Shah, P Gourh, ... The Journal of rheumatology 36 (10), 2250-2256, 2009 | 141 | 2009 |
| Does C‐reactive protein predict the long‐term progression of interstitial lung disease and survival in patients with early systemic sclerosis? X Liu, MD Mayes, C Pedroza, HT Draeger, EB Gonzalez, BE Harper, ... Arthritis care & research 65 (8), 1375-1380, 2013 | 136 | 2013 |
| Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis P Gourh, FC Arnett, FK Tan, S Assassi, D Divecha, G Paz, T McNearney, ... Annals of the rheumatic diseases 69 (3), 550-555, 2010 | 130 | 2010 |
| Association of the PTPN22 R620W polymorphism with anti–topoisomerase I– and anticentromere antibody–positive systemic sclerosis P Gourh, FK Tan, S Assassi, CW Ahn, TA McNearney, M Fischbach, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 126 | 2006 |
| Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile B Skaug, D Khanna, WR Swindell, ME Hinchcliff, TM Frech, VD Steen, ... Annals of the rheumatic diseases 79 (3), 379-386, 2020 | 124 | 2020 |
